TELA Bio (TELA) Expected to Announce Earnings on Tuesday

TELA Bio (NASDAQ:TELA) is projected to announce its Q4 2025 results after the market closes on Tuesday, March 24th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $21.0410 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:30 PM ET.

TELA Bio Stock Up 3.7%

Shares of NASDAQ:TELA opened at $0.78 on Monday. The company has a debt-to-equity ratio of 26.65, a quick ratio of 2.62 and a current ratio of 3.30. TELA Bio has a 1 year low of $0.67 and a 1 year high of $2.20. The stock has a market capitalization of $31.39 million, a P/E ratio of -0.87 and a beta of 0.88. The stock has a 50-day simple moving average of $0.86 and a 200-day simple moving average of $1.15.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Loop Capital set a $3.00 price target on shares of TELA Bio in a report on Monday, December 1st. Lake Street Capital reissued a “buy” rating on shares of TELA Bio in a research report on Monday, December 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TELA Bio in a research note on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, TELA Bio has an average rating of “Hold” and a consensus price target of $3.25.

Institutional Investors Weigh In On TELA Bio

Hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC boosted its holdings in TELA Bio by 161.3% in the 3rd quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock worth $53,000 after acquiring an additional 21,781 shares during the period. XTX Topco Ltd purchased a new stake in shares of TELA Bio during the fourth quarter valued at approximately $48,000. Renaissance Technologies LLC raised its stake in shares of TELA Bio by 101.4% during the fourth quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock valued at $152,000 after purchasing an additional 64,800 shares during the period. Finally, Susquehanna International Group LLP lifted its position in shares of TELA Bio by 551.2% during the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after purchasing an additional 72,594 shares in the last quarter. 94.35% of the stock is currently owned by hedge funds and other institutional investors.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.